Hu Yueming, Liu Ting, Tian Li, Cao Bohai, Xu Jinheng
Department of Pathology, Tangshan Central Hospital, Tangshan, China.
Department of Pathology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Cancer Invest. 2025 May;43(5):326-336. doi: 10.1080/07357907.2025.2512379. Epub 2025 Jun 11.
FARSB is a β-regulatory subunit of phenylalanine tRNA synthetase. It is reported that FARSB was involved in cancer progression. However, the molecular function of FARSB in breast cancer was unclear. This study aimed to investigate the prognostic significance of FARSB expression and its relationship with immunity in breast cancer.
Several databases, including TCGA, HPA, and UALCAN database, were applied to study FARSB mRNA and protein expression and its association with aggressiveness in breast cancer. We used immunohistochemical staining (IHC) to study FARSB expression in breast cancer and normal tissues. Chi square test was explored to study the correlation between FARSB expression and clinical features in breast cancer. Kaplan-Meier analysis and Cox regression were utilized to discuss the prognosis of breast cancer. Spearman analysis was applied to analyze the association between FARSB expression and immunity. We studied the correlation of FARSB with common breast cancer chemotherapeutic drugs. We conducted GO, KEGG, and GSEA enrichment analysis to study the molecular function of FARSB in breast cancer.
The TCGA database suggested that FARSB was increased in several cancers, including breast cancer. HPA and UALCAN databases suggested that FARSB protein expression was higher in breast cancer than normal tissues. IHC analysis also confirmed the higher expression of FARSB in breast cancer. FARSB expression had correlation with ER status and PR status. In TCGA database, FARSB expression was related to ER status, PR status, and PAM50. Overexpression FARSB had adverse prognosis, and Cox regression considered FARSB as a prognostic marker. Immunological analysis demonstrated that FARSB was linked with immune cell infiltration and immune checkpoints. High FARSB expression had low TIDE score. In addition, FARSB was linked to drugs, such as 5-fluorouracil, doxorubicin, gemcitabine, and paclitaxel. GSEA analysis suggested that FARSB was involved in the pathways, including cell cycle, aminoacyl TRNA biosynthesis, DNA replication, spliceosome, and mismatch repair.
FARSB was highly expression at mRNA and protein level in breast cancer. Overexpression of FARSB had a poor prognosis in breast cancer. FARSB expression was associated with immunity and acted as a new target for cancer immunological therapy.
FARSB是苯丙氨酸tRNA合成酶的β调节亚基。据报道，FARSB参与癌症进展。然而，FARSB在乳腺癌中的分子功能尚不清楚。本研究旨在探讨FARSB表达在乳腺癌中的预后意义及其与免疫的关系。
应用包括TCGA、HPA和UALCAN数据库在内的多个数据库，研究FARSB mRNA和蛋白表达及其与乳腺癌侵袭性的关联。我们采用免疫组织化学染色（IHC）研究FARSB在乳腺癌组织和正常组织中的表达。采用卡方检验研究FARSB表达与乳腺癌临床特征的相关性。利用Kaplan-Meier分析和Cox回归分析探讨乳腺癌的预后。应用Spearman分析分析FARSB表达与免疫的关联。我们研究了FARSB与常见乳腺癌化疗药物的相关性。进行GO、KEGG和GSEA富集分析以研究FARSB在乳腺癌中的分子功能。
TCGA数据库显示，FARSB在包括乳腺癌在内的多种癌症中表达增加。HPA和UALCAN数据库显示，FARSB蛋白在乳腺癌中的表达高于正常组织。IHC分析也证实了FARSB在乳腺癌中表达较高。FARSB表达与ER状态和PR状态相关。在TCGA数据库中，FARSB表达与ER状态、PR状态和PAM50相关。FARSB过表达具有不良预后，Cox回归将FARSB视为预后标志物。免疫分析表明，FARSB与免疫细胞浸润和免疫检查点相关。FARSB高表达具有较低的TIDE评分。此外，FARSB与5-氟尿嘧啶、阿霉素、吉西他滨和紫杉醇等药物相关。GSEA分析表明，FARSB参与细胞周期、氨酰tRNA生物合成、DNA复制、剪接体和错配修复等通路。
FARSB在乳腺癌中mRNA和蛋白水平均高表达。FARSB过表达在乳腺癌中预后不良。FARSB表达与免疫相关，可作为癌症免疫治疗的新靶点。
